<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966899</url>
  </required_header>
  <id_info>
    <org_study_id>312231</org_study_id>
    <nct_id>NCT02966899</nct_id>
  </id_info>
  <brief_title>Reversal of Right Ventricular Steatosis in Pulmonary Hypertension</brief_title>
  <official_title>Reversal of Right Ventricular Steatosis in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Providence VA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to elucidate the relationship between myocardial right ventricular
      triglyceride content (steatosis) and right ventricular dysfunction in participants with
      pulmonary hypertension, and investigate reversibility of this phenotype with omega-3 fatty
      acid treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to treat 30 participants that are identified as having elevated
      myocardial triglyceride content (defined as greater than 0.50%) on cardiac MRI with 4 grams
      of omega-3 fatty acids daily for six months with a primary end point of reducing right
      ventricular steatosis and a secondary endpoint of improving RV systolic function. The
      investigators hypothesize that right ventricular steatosis by cardiac MRI will be associated
      with the degree of right ventricular systolic function by cardiac MRI. In the subset of
      participants with elevated baseline steatosis who are treated with a lipoprotective strategy,
      the investigators hypothesize that six months of therapy with omega-3 fatty acids will reduce
      myocardial steatosis and improve right ventricular systolic function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular myocardial triglyceride content (by cardiac MRI) in 30 participants with pulmonary hypertension</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Right ventricular ejection fraction (by cardiac MRI) in 30 participants with pulmonary hypertension</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary; Hypertension</condition>
  <condition>Steatosis</condition>
  <condition>Right Ventricular Failure</condition>
  <arm_group>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women &gt; 30 years of age with a diagnosis of pulmonary hypertension
             (defined as mean pulmonary arterial pressure â‰¥25 mmHg at rest on right heart
             catheterization)

        Exclusion Criteria:

          -  Contraindication to MRI (e.g., metallic hazards or allergy to gadolinium)

          -  Renal dysfunction (eGFR &lt; 60 ml/min/1.73m2 as estimated by the Modified Diet in Renal
             Disease formula)

          -  High risk features for nephrogenic systemic fibrosis (solitary kidney or prior renal
             transplant)

          -  Active pregnancy or breastfeeding (determined by urinary pregnancy test before CMR)

          -  Weight &gt; 550 lb or waist diameter &gt; 70 cm (limits for our Siemens Verio CMR system)

          -  Fish Allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Providence VA Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siddique A Abbasi, MD</last_name>
      <phone>401-273-7100</phone>
      <phone_ext>2265</phone_ext>
      <email>siddique_abbasi@brown.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Providence VA Medical Center</investigator_affiliation>
    <investigator_full_name>Siddique Abbasi</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

